Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 101–200 of 1,025
Wykoff, C. C., Croft, D. E., Brown, D. M., Wang, R., Payne, J. F., Clark, L., Abdelfattah, N. S., & Sadda, S. R. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.009 · Cited by 275
Self-citationThe Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Campochiaro, P. A., Marcus, D. M., Awh, C. C., Regillo, C., Adamis, A. P., Bantseev, V., Chiang, Y., Ehrlich, J. S., Erickson, S., Hanley, W. D., et al. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2019.03.036 · Cited by 272
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
Gupta, O. P., Shienbaum, G., Patel, A. H., Fecarotta, C., Kaiser, R. S., & Regillo, C. D. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2010.02.032 · Cited by 272
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
“ANCHOR demonstrated similar results in eyes with predominantly classic choroidal neovascularization in AMD [ 4 ].”
ResultMolecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
“In the VEGF Inhibition Study in Ocular Neovascularization (VISION) trial, a phase 3 clinical trial, AMD eyes treated with pegaptanib were found to be less likely to develop severe vision loss than untreated eyes.135,136 Nevertheless, aflibercept also has similar efficacy as monthly ranibizumab injections, with less fr…”
MethodInfluentialReport from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium *
Csaky, K. G., Richman, E. A., & Ferris, F. L. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-1132 · Cited by 265
POLYPOIDAL CHOROIDAL VASCULOPATHY: Evidence-Based Guidelines for Clinical Diagnosis and Treatment
Koh, A. H. C., Chen, L.-J., Chen, S.-J., Chen, Y., Giridhar, A., Iida, T., Kim, H., Lai, T. Y. Y., Lee, W. K., Li, X., et al. (2013) · Retina · doi:10.1097/iae.0b013e3182852446 · Cited by 265
“In cases where CNV coexists with PCV or where a differential diagnosis is difficult, combination therapy would ensure that the standard of care is met for both conditions.(168,169) In circumstances where there is leakage from both components of PCV or where there is extensive subretinal fluid or exudation associated w…”
BackgroundMehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
CCR3 is a target for age-related macular degeneration diagnosis and therapy
Takeda, A., Baffi, J. Z., Kleinman, M. E., Cho, W. G., Nozaki, M., Yamada, K., Kaneko, H., Albuquerque, R. J. C., Dridi, S., Saito, K., et al. (2009) · Nature · doi:10.1038/nature08151 · Cited by 263
Mitochondrial DNA Damage as a Potential Mechanism for Age-Related Macular Degeneration
Karunadharma, P. P., Nordgaard, C. L., Olsen, T. W., & Ferrington, D. A. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5429 · Cited by 258
Roisman, L., Zhang, Q., Wang, R. K., Gregori, G., Zhang, A., Chen, C.-L., Durbin, M. K., An, L., Stetson, P. F., Robbins, G., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.01.044 · Cited by 261
Kodjikian, L., Souied, E. H., Mimoun, G., Mauget-Faÿsse, M., Behar-Cohen, F., Decullier, E., Huot, L., & Aulagner, G. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.06.020 · Cited by 257
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular Degeneration
Steinbrook, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068185 · Cited by 255
Long-term outcomes of treatment of neovascular age-related macular degeneration
Gillies, M. C., Campain, A., Barthelmes, D., Simpson, J. M., Arnold, J. J., Guymer, R. H., McAllister, I. L., Essex, R. W., Morlet, N., & Hunyor, A. P. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.010 · Cited by 254
Khanani, A. M., Kotecha, A., Chang, A., Chen, S.-J., Chen, Y., Guymer, R., Heier, J. S., Holz, F. G., Iida, T., Ives, J. A., et al. (2024) · Ophthalmology · doi:10.1016/j.ophtha.2024.02.014 · Cited by 227
Self-citationVascular endothelial growth factor and diabetic complications
WIROSTKO, B., WONG, T., & SIMO, R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.002 · Cited by 241
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Krohne, T. U., Liu, Z., Holz, F. G., & Meyer, C. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.03.047 · Cited by 238
RPE transplantation and its role in retinal disease
da Cruz, L., Chen, F. K., Ahmado, A., Greenwood, J., & Coffey, P. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.07.001 · Cited by 237
“This will allow us to anticipate the part it will play relative to treatments such as gene therapy, anti-vascular endothelial growth factor (VEGF) agents (Brown et al., 2006; Rosenfeld et al., 2006; Gragoudas et al., 2004), photodynamic therapy (PDT) (Michels and Schmidt-Erfurth, 2001), angiostatic steroids (Russell e…”
BackgroundResultRanibizumab According to Need: A Treatment for Age-related Macular Degeneration
Spaide, R. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.02.024 · Cited by 241
Ultrahigh-Speed Swept-Source OCT Angiography in Exudative AMD
Moult, E., Choi, W., Waheed, N. K., Adhi, M., Lee, B., Lu, C. D., Jayaraman, V., Potsaid, B., Rosenfeld, P. J., Duker, J. S., et al. (2014) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/23258160-20141118-03 · Cited by 235
Nguyen, Q. D., Das, A., Do, D. V., Dugel, P. U., Gomes, A., Holz, F. G., Koh, A., Pan, C. K., Sepah, Y. J., Patel, N., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.12.031 · Cited by 236
Bashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., & Noureddin, B. N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.031 · Cited by 236
Clinical pharmacology of intravitreal anti-VEGF drugs
Fogli, S., Del Re, M., Rofi, E., Posarelli, C., Figus, M., & Danesi, R. (2018) · Eye · doi:10.1038/s41433-018-0021-7 · Cited by 224
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
“3%-40%.(1,2) This improvement was associated with the drug’s ability to reduce intraretinal edema, subretinal fluid, and hemorrhage.”
Shah, C. P., Garg, S. J., Vander, J. F., Brown, G. C., Kaiser, R. S., & Haller, J. A. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.034 · Cited by 231
Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy
Simó, R., & Hernández, C. (2008) · Diabetologia · doi:10.1007/s00125-008-0989-9 · Cited by 228
Stewart, M. W., Rosenfeld, P. J., Penha, F. M., Wang, F., Yehoshua, Z., Bueno-Lopez, E., & Lopez, P. F. (2011) · Retina · doi:10.1097/iae.0b013e31822c290f · Cited by 225
Axl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Ruan, G., & Kazlauskas, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.21 · Cited by 223
“Ranibizumab (Lucentis), an antibody fragment developed from bevacizumab, is an FDA-approved treatment for neo-vascular age-related macular degeneration (AMD) (Brown et al , 2006; Rosenfeld et al , 2006).”
Willoughby, A. S., Ying, G.-S., Toth, C. A., Maguire, M. G., Burns, R. E., Grunwald, J. E., Daniel, E., Jaffe, G. J., Williams, D. F., Beardsley, S., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.05.042 · Cited by 220
“Anti-VEGF therapy decreases endothelium permeability, thereby reducing vascular fluid leakage, but it is less effective at decreasing the size of the neovascular complex.(1,2,7,11,12) We hypothesize that the rapid decrease in SHRM thickness is caused by a reduction in the SHRM fluid component induced by antiVEGF thera…”
BackgroundPrinciples of pharmacology in the eye
Awwad, S., Mohamed Ahmed, A. H. A., Sharma, G., Heng, J. S., Khaw, P. T., Brocchini, S., & Lockwood, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14024 · Cited by 224
“Both the ANCHOR and MARINA trials examined visual outcomes after monthly dosing of ranibizumab, a humanized monoclonal antibody fragment antigen-binding (Brown et al., 2006; Rosenfeld et al., 2006).”
Chong, E. W.-T., Wong, T. Y., Kreis, A. J., Simpson, J. A., & Guymer, R. H. (2007) · BMJ · doi:10.1136/bmj.39350.500428.47 · Cited by 225
A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis
Kim, L. A., & D'Amore, P. A. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.06.006 · Cited by 220
Brown, D. M., & Regillo, C. D. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.06.039 · Cited by 224
Self-citationRanibizumab in neovascular age-related macular degeneration
Eng, K. T., & Kertes, P. J. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.4.451 · Cited by 216
“Their results are summarized below (Brown et al 2006; Rosenfeld et al 2006).”
Anti-VEGF Treatment Strategies for Wet AMD
Kovach, J. L., Schwartz, S. G., Flynn, H. W., & Scott, I. U. (2012) · Journal of Ophthalmology · doi:10.1155/2012/786870 · Cited by 220
“5 letters in the verteporfin group [21].”
BackgroundWhitmore, S. S., Sohn, E. H., Chirco, K. R., Drack, A. V., Stone, E. M., Tucker, B. A., & Mullins, R. F. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.11.005 · Cited by 218
Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches
Ricci, F., Bandello, F., Navarra, P., Staurenghi, G., Stumpp, M., & Zarbin, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218242 · Cited by 208
“ANCHOR [90,93] 2 years Group I Group II Group III”
BackgroundKaiser, P. K., Blodi, B. A., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.04.030 · Cited by 217
Self-citationINCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB
FINTAK, D. R., SHAH, G. K., BLINDER, K. J., REGILLO, C. D., POLLACK, J., HEIER, J. S., HOLLANDS, H., & SHARMA, S. (2008) · Retina · doi:10.1097/iae.0b013e3181884fd2 · Cited by 214
Self-citationMicroRNAs Regulate Ocular Neovascularization
Shen, J., Yang, X., Xie, B., Chen, Y., Swaim, M., Hackett, S. F., & Campochiaro, P. A. (2008) · Molecular Therapy · doi:10.1038/mt.2008.104 · Cited by 214
Current progress in the derivation and therapeutic application of neural stem cells
Tang, Y., Yu, P., & Cheng, L. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.504 · Cited by 211
“Age-related macular degeneration (AMD) is characterized by a progressive loss of photoreceptors, and it is the leading cause of vision loss.(112) Although treatment options for AMD are limited, transplantation of human NPCs into a rodent model of retinal degeneration not only halted the progression of vision loss but…”
BackgroundNeovascular Age-Related Macular Degeneration: Potential Therapies
Chappelow, A. V., & Kaiser, P. K. (2008) · Drugs · doi:10.2165/00003495-200868080-00002 · Cited by 213
Self-citationTufail, A., Patel, P. J., Egan, C., Hykin, P., da Cruz, L., Gregor, Z., Dowler, J., Majid, M. A., Bailey, C., Mohamed, Q., et al. (2010) · BMJ · doi:10.1136/bmj.c2459 · Cited by 213
Okada, M., Mitchell, P., Finger, R. P., Eldem, B., Talks, S. J., Hirst, C., Paladini, L., Barratt, J., Wong, T. Y., & Loewenstein, A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.060 · Cited by 214
Schmidt-Erfurth, U., Waldstein, S. M., Deak, G.-G., Kundi, M., & Simader, C. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.017 · Cited by 211
Bhisitkul, R. B., Mendes, T. S., Rofagha, S., Enanoria, W., Boyer, D. S., Sadda, S. R., & Zhang, K. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.01.032 · Cited by 210
Pseudoxanthoma Elasticum: Genetics, Clinical Manifestations and Therapeutic Approaches
Finger, R. P., Issa, P. C., Ladewig, M. S., Götting, C., Szliska, C., Scholl, H. P. N., & Holz, F. G. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2008.12.006 · Cited by 212
Fully automated detection of retinal disorders by image-based deep learning
Li, F., Chen, H., Liu, Z., Zhang, X., & Wu, Z. (2019) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-018-04224-8 · Cited by 208
Bressler, S. B. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.045 · Cited by 205
Ferrara, N. (2010) · Nature Medicine · doi:10.1038/nm1010-1107 · Cited by 203
Recent developments in the treatment of age-related macular degeneration
Holz, F. G., Schmitz-Valckenberg, S., & Fleckenstein, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71029 · Cited by 206
“and significantly improved vision in over 30% of patients (53, 54) (MARINA, NCT00056836; ANCHOR trial, NCT00061594).”
Growth of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials
Grunwald, J. E., Pistilli, M., Ying, G.-S., Maguire, M. G., Daniel, E., & Martin, D. F. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.007 · Cited by 204
“Four single nucleotide polymorphisms (SNPs) previously associated with the risk of developing AMD were evaluated for association with growth of GA: (1) complement factor H (CFH) Y402H (rs1061170), (2) age-related maculopathy susceptibility 2 (ARMS2, also called LOC387715) A69S (rs10490924), (3) high temperature requir…”
BackgroundMethodCurrent update on retinopathy of prematurity: screening and treatment
Chen, J., Stahl, A., Hellstrom, A., & Smith, L. E. (2011) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e3283423f35 · Cited by 203
Xu, L., Lu, T., Tuomi, L., Jumbe, N., Lu, J., Eppler, S., Kuebler, P., Damico-Beyer, L. A., & Joshi, A. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10260 · Cited by 201
Ciulla, T. A., Hussain, R. M., Pollack, J. S., & Williams, D. F. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2019.05.017 · Cited by 201
The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
Stewart, M. W. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2011.10.001 · Cited by 204
Cohen, S. Y., Mimoun, G., Oubraham, H., Zourdani, A., Malbrel, C., Queré, S., & Schneider, V. (2013) · Retina · doi:10.1097/iae.0b013e31827b6324 · Cited by 198
Schmidt-Erfurth, U., Bogunovic, H., Sadeghipour, A., Schlegl, T., Langs, G., Gerendas, B. S., Osborne, A., & Waldstein, S. M. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2017.03.015 · Cited by 199
Maharaj, A. S. R., & D'Amore, P. A. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.03.004 · Cited by 195
“The first FDA-approved antiVEGF therapy, bevacizumab (Avastin™, Genentech) was introduced into the clinics in 2004 in combination with Irinotecan, fluorouracil, or leucovorin for the treatment of metastatic colorectal cancer (mCRC) [70] and more recently for the combination treatment of advanced non-small-cell lung ca…”
BackgroundDrug Delivery to the Eye: What Benefits do Nanocarriers offer?
Joseph, R. R., & Venkatraman, S. S. (2017) · Nanomedicine · doi:10.2217/nnm-2016-0379 · Cited by 192
Incidence of Endophthalmitis and Use of Antibiotic Prophylaxis after Intravitreal Injections
Cheung, C. S. Y., Wong, A. W. T., Lui, A., Kertes, P. J., Devenyi, R. G., & Lam, W.-C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.014 · Cited by 197
Jung, J. J., Chen, C. Y., Mrejen, S., Gallego-Pinazo, R., Xu, L., Marsiglia, M., Boddu, S., & Freund, K. B. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.07.006 · Cited by 195
“Large randomized clinical trials have selected distinct lesion types for inclusion criteria because they were believed to respond differently to treatment.(9,10,44) It is also well known that some patients with type 1 neovascular AMD may experience little or no vision loss.”
BackgroundMethodENGELBERT, M., ZWEIFEL, S. A., & FREUND, K. B. (2009) · Retina · doi:10.1097/iae.0b013e3181bfbd46 · Cited by 192
Prenner, J. L., Halperin, L. S., Rycroft, C., Hogue, S., Williams Liu, Z., & Seibert, R. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.06.023 · Cited by 195
Curtis, L. H. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.223 · Cited by 193
Yaspan, B. L., Williams, D. F., Holz, F. G., Regillo, C. D., Li, Z., Dressen, A., van Lookeren Campagne, M., Le, K. N., Graham, R. R., Beres, T., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf1443 · Cited by 186
“Because there is risk without potential benefit with a placebo intravitreal injection, sham injections have served as the acceptable control for study drug injections (29, 30).”
BackgroundAntoszyk, A. N., Tuomi, L., Chung, C. Y., & Singh, A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.029 · Cited by 190
Visual acuity as an outcome measure in clinical trials of retinal diseases
Beck, R. W., Maguire, M. G., Bressler, N. M., Glassman, A. R., Lindblad, A. S., & Ferris, F. L. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.06.047 · Cited by 188
VEGF inhibition: insights from preclinical and clinical studies
Crawford, Y., & Ferrara, N. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0675-8 · Cited by 188
“One is verteporfin (Visudyne) photodynamic therapy (PDT; TAP Study Group 1999) for only predominantly classic lesions, in which 50% or more of the lesion consist of classic choroidal neovascularization (CNV).”
ResultInfluentialKhanani, A. M., Aziz, A. A., Khan, H., Gupta, A., Mojumder, O., Saulebayeva, A., Abbey, A. M., Almeida, D. R. P., Avery, R. L., Banda, H. K., et al. (2023) · Eye · doi:10.1038/s41433-023-02553-5 · Cited by 180
Holz, F. G., Dugel, P. U., Weissgerber, G., Hamilton, R., Silva, R., Bandello, F., Larsen, M., Weichselberger, A., Wenzel, A., Schmidt, A., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.12.030 · Cited by 184
Kim, L. N., Mehta, H., Barthelmes, D., Nguyen, V., & Gillies, M. C. (2016) · Retina · doi:10.1097/iae.0000000000001142 · Cited by 184
“The aim of this metaanalysis was to assess whether the impressive outcomes demonstrated from Phase 3 clinical trials translate to real-world clinical practice.(5) We paid particular attention to how visual acuity (VA) outcomes vary according to different treatment regimens across the world.”
BackgroundComparison of Natamycin and Voriconazole for the Treatment of Fungal Keratitis
Prajna, N. V. (2010) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.102 · Cited by 183
Pilli, S., Kotsolis, A., Spaide, R. F., Slakter, J., Freund, K. B., Sorenson, J., Klancnik, J., & Cooney, M. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.12.036 · Cited by 181
Oxidation and age-related macular degeneration: insights from molecular biology
Khandhadia, S., & Lotery, A. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239941000164x · Cited by 181
Moshfeghi, A. A., Rosenfeld, P. J., Flynn, H. W., Schwartz, S. G., Davis, J. L., Murray, T. G., Smiddy, W. E., Berrocal, A. M., Dubovy, S. R., Lee, W.-H., et al. (2011) · Retina · doi:10.1097/iae.0b013e31821067c4 · Cited by 181
Kumar, N., Marsiglia, M., Mrejen, S., Fung, A. T.-C., Slakter, J., Sorenson, J., & Freund, K. B. (2013) · Retina · doi:10.1097/iae.0b013e31828e8551 · Cited by 177
MULTIMODAL IMAGING OF PIGMENT EPITHELIAL DETACHMENT: A Guide to Evaluation
Mrejen, S., sarraf, D., mukkamala, S. K., & freund, K. B. (2013) · Retina · doi:10.1097/iae.0b013e3182993f66 · Cited by 178
“In the MARINA (occult arm) and ANCHOR (classic arm) studies, eyes with occult CNV presented with better visual acuity at baseline and had less visual improvement (mean of +7 letters and 34% 3-line gainers) than eyes with Type 2 classic CNV (mean of +11 letters and 40% 3-line gainers) after monthly ranibizumab intravit…”
BackgroundThe Vision Academy Steering Committee, Lanzetta, P., & Loewenstein, A. (2017) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3647-4 · Cited by 180
Arnold, J. J., Campain, A., Barthelmes, D., Simpson, J. M., Guymer, R. H., Hunyor, A. P., McAllister, I. L., Essex, R. W., Morlet, N., Gillies, M. C., et al. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.02.009 · Cited by 181
Vascular endothelial growth factor biology: clinical implications for ocular treatments
Bhisitkul, R. B. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.098426 · Cited by 181
Simader, C., Ritter, M., Bolz, M., Deák, G. G., Mayr-Sponer, U., Golbaz, I., Kundi, M., & Schmidt-Erfurth, U. M. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.12.029 · Cited by 177
From oxygen to erythropoietin: Relevance of hypoxia for retinal development, health and disease
Caprara, C., & Grimm, C. (2012) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2011.11.003 · Cited by 176
Yamazaki, T., Koizumi, H., Yamagishi, T., & Kinoshita, S. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.022 · Cited by 175
Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature
Stanescu-Segall, D., Balta, F., & Jackson, T. L. (2016) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.04.004 · Cited by 175
Therapeutic targets in age-related macular disease
Bird, A. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42437 · Cited by 175
Augood, C., Chakravarthy, U., Young, I., Vioque, J., de Jong, P. T., Bentham, G., Rahu, M., Seland, J., Soubrane, G., Tomazzoli, L., et al. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.398 · Cited by 176
“Despite recent advances in the treatment of NV-AMD (3, 4), this condition remains a major cause of significant visual morbidity.”
BackgroundSelf-citationEnnis, S., Jomary, C., Mullins, R., Cree, A., Chen, X., MacLeod, A., Jones, S., Collins, A., Stone, E., & Lotery, A. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61348-3 · Cited by 171
Sultan, M. B., Zhou, D., Loftus, J., Dombi, T., & Ice, K. S. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.045 · Cited by 172
Waldstein, S. M., Simader, C., Staurenghi, G., Chong, N. V., Mitchell, P., Jaffe, G. J., Lu, C., Katz, T. A., & Schmidt-Erfurth, U. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.037 · Cited by 172
Bakri, S. J., Thorne, J. E., Ho, A. C., Ehlers, J. P., Schoenberger, S. D., Yeh, S., & Kim, S. J. (2019) · Ophthalmology · doi:10.1016/j.ophtha.2018.07.028 · Cited by 167
Sun~er, I. J., Kokame, G. T., Yu, E., Ward, J., Dolan, C., & Bressler, N. M. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3225 · Cited by 170
“measured at 2 m at each visit and at 4 m at day 0, month 12, and month 24.(24) NEI VFQ-25 Methods”
BackgroundResultInfluentialKokame, G. T., Yeung, L., & Lai, J. C. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150029 · Cited by 168
“3% of patients treated with monthly ranibizumab gained$15 letters at 12 months.(19) In the MARINA trial for occult CNV, 33.”
BackgroundMethodResultInfluentialNakazawa, T., Takeda, M., Lewis, G. P., Cho, K.-S., Jiao, J., Wilhelmsson, U., Fisher, S. K., Pekny, M., Chen, D. F., & Miller, J. W. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1398 · Cited by 168
Lowe, J., Araujo, J., Yang, J., Reich, M., Oldendorp, A., Shiu, V., Quarmby, V., Lowman, H., Lien, S., Gaudreault, J., et al. (2007) · Experimental Eye Research · doi:10.1016/j.exer.2007.05.008 · Cited by 167
Age-related macular degeneration and the complement system
Khandhadia, S., Cipriani, V., Yates, J. R. W., & Lotery, A. J. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.07.019 · Cited by 167
Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab Injections
Adelman, R. A., Zheng, Q., & Mayer, H. R. (2010) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2009.0076 · Cited by 169
Preclinical safety evaluation of AAV2-sFLT01— a gene therapy for age-related macular degeneration
MacLachlan, T. K., Lukason, M., Collins, M., Munger, R., Isenberger, E., Rogers, C., Malatos, S., DuFresne, E., Morris, J., Calcedo, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.258 · Cited by 166
CHAN, C. K., MEYER, C. H., GROSS, J. G., ABRAHAM, P., NUTHI, A. S. D., KOKAME, G. T., LIN, S. G., RAUSER, M. E., & KAISER, P. K. (2007) · Retina · doi:10.1097/iae.0b013e3180cc2612 · Cited by 166
Self-citation
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.